Publication — IRIC

Cost-Effectiveness Analysis of a HMGA2 Prognostic Test for Acute Myeloid Leukemia in a Canadian Setting.

Current strategies for risk stratification of patients with acute myeloid leukemia assign approximately 40% of patients to the intermediate-risk group, where uncertainty about optimal therapy still persists.

Publication date
December 2, 2019
Principal Investigators
Tremblay G, Rousseau B, Marquis M, Beaubois C, Sauvageau G, Hébert J
PubMed reference
Appl Health Econ Health Policy 2019;17(6):827-839
PubMed ID
31392669
Affiliation
Purple Squirrel Economics, New York, NY, USA. gabrielt.ecn@gmail.com.